Myopathies under therapy with lipid-lowering agents;Myopathien unter der therapie mit lipidsenkern

Nervenarzt

Volumn 76, Issue 2, 2005, Pages 212-217

  Koller H ^a,b   Neuhaus, O ^a   Schroeter, M ^a   Hartung, H P ^a  

^a HEINRICH HEINE UNIVERSITY   (Germany)

^b UNIVERSITY HOSPITAL DÜSSELDORF   (Germany)

Author keywords

Differential diagnosis; Lipid lowering agents; Myopathies; Rhabdomyolysis; Side effects

Indexed keywords

ANTILIPEMIC AGENT; ATORVASTATIN; CERIVASTATIN; CLARITHROMYCIN; CREATINE KINASE; CYCLOSPORIN A; DILTIAZEM; ERYTHROMYCIN; EZETIMIBE; FIBRIC ACID DERIVATIVE; FLUINDOSTATIN; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; ITRACONAZOLE; KETOCONAZOLE; LIDOCAINE; MACROLIDE; MEVINOLIN; MIDAZOLAM; NIFEDIPINE; PLACEBO; SIMVASTATIN; STATIN; VERAPAMIL; WARFARIN;

ARTICLE; CLINICAL FEATURE; DRUG EXCRETION; DRUG METABOLISM; HISTOPATHOLOGY; HUMAN; HYPERLIPIDEMIA; INCIDENCE; MUSCLE CRAMP; MYALGIA; MYOPATHY; PRESCRIPTION; RHABDOMYOLYSIS; SIDE EFFECT;

ANTICHOLESTEREMIC AGENTS; CLOFIBRIC ACID; DIAGNOSIS, DIFFERENTIAL; DOSE-RESPONSE RELATIONSHIP, DRUG; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; MUSCULAR DISEASES; PHYSICIAN'S PRACTICE PATTERNS; PRACTICE GUIDELINES; PROGNOSIS; RHABDOMYOLYSIS; TREATMENT OUTCOME;

EID: 14544303695     PISSN: 00282804     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00115-004-1837-x     Document Type: Article

References (35)

1. Baker SK, Tarnopolsky MA (2001) Statin myopathies: pathophysiologic and clinical perspectives. Clin Invest Med 24:258-272
2. Bandoh T, Mitani H, Niihashi M et al. (2000) Fluvastatin suppresses atherosclerotic progression, mediated through its inhibitory effect on endothelial dysfunction, lipid peroxidation, and macrophage deposition. J Cardiovasc Pharmacol 35:136-144
3. Bays HE, Moore PB, Drehobl MA et al. (2001) Effectiveness and tolerability of ezetimibe in patients with primary hypercholesterolemia: pooled analysis of two phase II studies. Clin Ther 23:1209-1230
4. Chang JT, Staffa JA, Parks M et al. (2004) Rhabdomyolysis with HMG-CoA reductase inhibitors and gemfibrozil combination therapy. Pharmacoepidemiol Drug Saf 13:417-426
5. Charatan F (2001) Bayer decides to withdraw cholesterol lowering drug. Br Med J 323:359
6. De Pinieux G, Chariot P, Ammi-Said M et al. (1996) Lipid-lowering drugs and mitochondrial function: effects of HMG-CoA reductase inhibitors on serum ubiquinone and blood lactate/pyruvate ratio. Br J Clin Pharmacol 42:333-337
7. DiMauro S, Bonilla E, Davidson M et al. (1998) Mitochondria in neuromuscular disorders. Biochim Biophys Acta 1366:199-210
8. Dreier JP, Endres M (2004) Statin-associated rhabdomyolysis triggered by grapefruit consumption. Neurology 62:670
9. Farmer JA (2003) Statins and myotoxicity. Curr Atheroscler Rep 5:96-100
10. Floris S, Blezer EL, Schreibelt G et al. (2004) Blood-brain barrier permeability and monocyte infiltration in experimental allergic encephalomyelitis: a quantitative MRI study. Brain 127:616-627
11. Fux R, Morike K, Gundel UF et al. (2004) Ezetimibe and statin-associated myopathy. Ann Intern Med 140:671-672
12. Gaist D, Rodriguez LA, Huerta C et al. (2001) Lipid-lowering drugs and risk of myopathy: a population-based follow-up study. Epidemiology 12:565-569
13. Gotto AM Jr (2003) Risks and benefits of continued aggressive statin therapy. Clin Cardiol 26:1113-12
14. 13a. Graham DJ, Staffa JA, Shatin D et al. (2004) Incidence of hospitalized rhabdomyolysis in patients treated with lipid-lowering drugs. JAMA 292:2585-2590
15. Ikeda U, Shimada K (1999) Statins and monocytes. Lancet 353:2070
16. Jamal SM, Eisenberg MJ, Christopoulos S (2004) Rhabdomyolysis associated with hydroxymethylglutaryl-coenzyme A reductase inhibitors. Am Heart J 147:956-965
17. Kivisto KT, Niemi M, Schaeffeler E et al. (2004) Lipid-lowering response to statins is affected by CYP3A5 polymorphism. Pharmacogenetics 14:523-525
18. Laaksonen R, Jokelainen K, Sahi T et al. (1995) Decreases in serum ubiquinone concentrations do not result in reduced levels in muscle tissue during short-term simvastatin treatment in humans. Clin Pharmacol Ther 57:62-66
19. Laufs U, Gertz K, Huang P et al. (2000) Atorvastatin upregulates type III nitric oxide synthase in thrombocytes, decreases platelet activation, and protects from cerebral ischemia in normocholesterolemic mice. Stroke 31:2442-2449
20. Maron DJ, Fazio S, Linton MF (2000) Current perspectives on statins. Circulation 101:207-213
21. Matzno S, Tazuya-Murayama K, Tanaka H et al. (2003) Evaluation of the synergistic adverse effects of concomitant therapy with statins and fibrates on rhabdomyolysis. J Pharm Pharmacol 55:795-802
22. Neuhaus O, Strasser-Fuchs S, Fazekas F et al. (2002) Statins as immunomodulators: comparison with interferon-beta 1b in MS. Neurology 59:990-997
23. Neuhaus O, Stüve O, Zamvil SS et al. (2004) Are statins a treatment option in multiple sclerosis? Lancet Neurol 3:369-371
24. Neuhaus O, Wiendl H, Kieseier BC et al. (2003) Cholesterinsenker - eine neue Therapieoption bei Multipler Sklerose? Statine als Immunmodulatoren. Nervenarzt 74:704-707
25. Pasternak RC, Smith SC Jr, Bairey-Merz CN et al. (2002) ACC/AHA/NHLBI clinical advisory on the use and safety of statins. Stroke 33:2337-2341
26. Phillips PS, Haas RH, Bannykh S et al. (2002) Statin-associated myopathy with normal creatine kinase levels. Ann Intern Med 137:581-585
27. Rando LP, Cording SA, Newnham HH (2004) Successful reintroduction of statin therapy after myositis: was there another cause? Med J Aust 180:472-473
28. Schaefer WH, Lawrence JW, Loughlin AF et al. (2004) Evaluation of ubiquinone concentration and mitochondrial function relative to cerivastatin-induced skeletal myopathy in rats. Toxicol Appl Pharmacol 194:10-23
29. Shek A, Ferrill MJ (2001) Statin-fibrate combination therapy. Ann Pharmacother 35:908-917
30. Sinzinger H, O'Grady J (2004) Professional athletes suffering from familial hypercholesterolaemia rarely tolerate statin treatment because of muscular problems. Br J Clin Pharmacol 57:525-528
31. Staffa JA, Chang J, Green L (2002) Cerivastatin and reports of fatal rhabdomyolysis. N Engl J Med 346:539-540
32. Thompson PD, Clarkson P, Karas RH (2003) Statin-associated myopathy. JAMA 289:1681-1690
33. Wortmann RL (2002) Lipid-lowering agents and myopathy. Curr Opin Rheumatol 14:643-647
34. Yan L, Lan F, Wang ZG et al. (2003) Statins and myotoxicity. Trends Pharmacol Sci 24:113-114
35. Youssef S, Stuve O, Patarroyo JC et al. (2002) The HMG-CoA reductase inhibitor, atorvastatin, promotes a Th2 bias and reverses paralysis in central nervous system autoimmune disease. Nature 420:78-84